BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News $29.36 +2.20 (+8.11%) Closing price 11:51 AM EasternExtended Trading$29.36 +0.00 (+0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock About Franklin Genomic Advancements ETF (BATS:HELX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HELX alerts:Sign Up Key Stats Today's Range$27.55▼$27.5550-Day Range$27.00▼$29.5852-Week Range$23.74▼$33.93Volume2,058 shsAverage Volume3,767 shsMarket Capitalization$11.74 millionAssets Under Management$14.67 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton. Read More Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.56%0.57%0.53%Other Expenses0.00%0.57%0.56%0.48%0.56%Total Expense0.50%0.74%0.76%0.71%0.73%Fee Waiver0.00%-0.76%-0.66%-0.46%-0.63%Net Expense0.50%0.60%0.63%0.64%0.60% Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HELX ETF News HeadlinesFranklin Genomic Advancements ETF - Markets InsiderJuly 23, 2025 | markets.businessinsider.comFranklin Emerging Markets UCITS ETF (FLXE)September 18, 2024 | investing.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 21 at 2:00 AM | Weiss Ratings (Ad)Franklin Ethereum ETF (EZET)August 2, 2024 | finance.yahoo.comChainlink Integration Enhances Transparency for 21Shares’ Ether ETFJuly 30, 2024 | msn.comFranklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)April 23, 2024 | lse.co.ukSee More Headlines HELX ETF - Frequently Asked Questions How have HELX shares performed this year? Franklin Genomic Advancements ETF's stock was trading at $28.85 at the beginning of 2025. Since then, HELX shares have increased by 1.8% and is now trading at $29.3590. Who are Franklin Genomic Advancements ETF's major shareholders? Franklin Genomic Advancements ETF's top institutional investors include Raymond James Financial Inc. (0.38%). How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Franklin Genomic Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), Abiomed (ABMD), Catalent (CTLT), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Net Element (NETE), Novavax (NVAX) and AbbVie (ABBV). Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings66 Fund Statistics Assets Under Management$14.67 million Average Daily Volume$0.00 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianState Street Bank and Trust Company DistributorFranklin Templeton Distributors, Inc. Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Miscellaneous Outstanding Shares400,000Beta1.05 Creation Unit50,000 Creation Fee$200.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 HELX HoldingsNatera (NASDAQ:NTRA)Holding Weight: 5.28%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 4.53%Medpace (NASDAQ:MEDP)Holding Weight: 4.38%Samsung Biologics Co.,Ltd.Holding Weight: 4.28%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.26%Krystal Biotech (NASDAQ:KRYS)Holding Weight: 3.77%Insmed (NASDAQ:INSM)Holding Weight: 3.53%Us DollarHolding Weight: 3.39%Guardant Health (NASDAQ:GH)Holding Weight: 3.34%Corteva (NYSE:CTVA)Holding Weight: 3.21%Full Holdings DetailsHELX Sector ExposureHELX Industry Exposure This page (BATS:HELX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access